Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma

Current Eye Research

Volumn 35, Issue 5, 2010, Pages 435-439

  Landreville, Solange ^a   Ma, Duanduan ^a   Wu, Jun ^a   Harbour, J William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Id2; Pocket proteins; Rb protein; Retinoblastoma; Tumor suppressor

Indexed keywords

INHIBITOR OF DIFFERENTIATION 2; MESSENGER RNA; RETINOBLASTOMA PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CROSS BREEDING; GENE INACTIVATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRAOCULAR TUMOR; MITOSIS INDEX; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENOTYPE; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; RETINAL NEOPLASMS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 77952155969     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903509428     Document Type: Article

References (30)

1. Yokota Y. Id and development. Oncogene. 2001;20:8290-8298.
2. Sikder HA, Devlin MK, Dunlap S, et al. Id proteins in cell growth and tumorigenesis. Cancer Cell. 2003;3:525-530.
3. Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene. 2006;25:5326-5332.
4. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene. 2001;20:8326-8333.
5. Kleeff J, Ishiwata T, Friess H, et al. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res. 1998;58:3769-3772.
6. Lasorella A, Boldrini R, Dominici C, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res. 2002;62:301-306.
7. Iavarone A, Garg P, Lasorella A, et al. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994;8:1270-1284.
8. Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Molec Cell Biol. 1996;16:2570-2578.
9. Lasorella A, Noseda M, Beyna M, et al. Id2 is a retinoblastoma protein target and mediates signaling by Myc oncoproteins. Nature. 2000;407:592-598.
10. Lasorella A, Rothschild G, Yokota Y, et al. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol. 2005;25:3563-3574.
11. Nilsson JA, Nilsson LM, Keller U, et al. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res. 2004;64: 7296-7301.
12. Murphy DJ, Swigart LB, Israel MA, et al. Id2 is dispensable for Myc-induced epidermal neoplasia. Mol Cell Biol. 2004;24:2083-2090.
13. Itahana Y, Singh J, Sumida T, et al. Role of Id2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res. 2003;63:7098-7105.
14. Russell RG, Lasorella A, Dettin LE, et al. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium. Cancer Res. 2004;64:7220-7225.
15. Kowanetz M, Valcourt U, Bergstrom R, et al. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol. 2004;24:4241-4254.
16. Ashizawa S, Nishizawa H, Yamada M, et al. Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression. J Biol Chem. 2001;4:4.
17. Harbour JW, Luo RX, Dei Sante A, et al. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98:859-869.
18. Lukas J, Sorensen CS, Lukas C, et al. p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: Molecular mechanisms and implications for oncogenesis. Oncogene. 1999;18:3930-3935.
19. Ma D, Zhou P, Harbour JW. Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J Biol Chem. 2003;278:19358-19366.
20. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66:4602-4609.
21. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
22. Yokota Y, Mansouri A, Mori S, et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature. 1999;397:702-706.
23. Eagle RC, Jr. High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med. 2009;133:1203-1209.
24. Chakraborty S, Khare S, Dorairaj SK, et al. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics. 2007;90:344-353. (Pubitemid 47176334)
25. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46:617-634.
26. Tsunedomi R, Iizuka N, Tamesa T, et al. Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res. 2008;14:1025-1031.
27. Chaudhary J, Schmidt M, Sadler-Riggleman I. Negative acting HLH proteins Id 1, Id 2, Id 3, and Id 4 are expressed in prostate epithelial cells. Prostate. 2005;64:253-264.
28. Jockovich ME, Murray TG, Escalona-Benz E, et al. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
29. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;47:1-16.
30. Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63: 511-518. (Pubitemid 26420792)